A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
Active, not recruiting · NCT04786028 · Registry updated 2025-01-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2025-01-08 | NCT04786028 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Myeloma Research Group | 4 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allan Blair Cancer Centre | Regina | Canada | 1 |
| Cross Cancer Institute | Edmonton | Canada | 6 |
| Hamilton Health Sciences Centre | Hamilton | Canada | 1 |
| Nova Scotia Health - QEII Health Sciences Centre | Halifax | Canada | 1 |
| Princess Margaret Cancer Centre | Toronto | Canada | 1 |
| Saskatoon Cancer Center | Saskatoon | Canada | 4 |
| The Ottawa Hospital General Campus | Ottawa | Canada | 1 |